Array ( [0] => {{Short description|Immunosuppressive drug}} [1] => {{Use British English|date=April 2020}} [2] => {{Use dmy dates|date=January 2024}} [3] => {{cs1 config |name-list-style=vanc |display-authors=6}} [4] => {{Infobox drug [5] => | Verifiedfields = changed [6] => | Watchedfields = changed [7] => | verifiedrevid = 461746192 [8] => | image = Tacrolimus2DCSD.svg [9] => | width = 250 [10] => | alt = [11] => | image2 = Tacrolimus-1YAT-ball-and-stick-model.png [12] => | width2 = 250 [13] => | alt2 = [14] => | caption = [15] => [16] => [17] => | pronounce = [18] => | tradename = Prograf, Advagraf, Protopic, others [19] => | Drugs.com = {{drugs.com|monograph|tacrolimus}} [20] => | MedlinePlus = a601117 [21] => | DailyMedID = Tacrolimus [22] => | pregnancy_AU = C [23] => | pregnancy_AU_comment = {{cite web | title=Tacrolimus Use During Pregnancy | website=Drugs.com | date=3 October 2019 | url=https://www.drugs.com/pregnancy/tacrolimus.html | access-date=29 April 2020}} [24] => | pregnancy_category= [25] => | routes_of_administration = [[Topical administration|Topical]], [[Oral administration|by mouth]], [[Intravenous therapy|intravenous]] [26] => | class = [27] => | ATC_prefix = D11 [28] => | ATC_suffix = AH01 [29] => | ATC_supplemental=
{{ATC|L04|AD02}} [30] => [31] => [32] => | legal_AU = [33] => | legal_AU_comment = [34] => | legal_BR = [35] => | legal_BR_comment = [36] => | legal_CA = Rx-only [37] => | legal_CA_comment ={{cite web | title=Drug and medical device highlights 2019: Helping you maintain and improve your health | website=[[Health Canada]] | date=18 November 2020 | url=https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/drug-medical-device-highlights-2019.html | access-date=28 March 2024}} [38] => | legal_DE = [39] => | legal_DE_comment = [40] => | legal_NZ = [41] => | legal_NZ_comment = [42] => | legal_UK = [43] => | legal_UK_comment = [44] => | legal_US = Rx-only [45] => | legal_US_comment = {{cite web | title=Prograf- tacrolimus capsule, gelatin coated Prograf- tacrolimus injection, solution Prograf- tacrolimus granule, for suspension | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f667de1-9dfa-4bd6-8ba0-15ee2d78873b | access-date=16 July 2021}} [46] => | legal_EU = Rx-only [47] => | legal_EU_comment = {{cite web | title=Advagraf EPAR | website=European Medicines Agency | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/advagraf | access-date=16 July 2021}}{{cite web | title=Protopic EPAR | website=European Medicines Agency | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/protopic | access-date=16 July 2021}} [48] => | legal_UN = [49] => | legal_UN_comment = [50] => | legal_status = Rx-only [51] => [52] => [53] => | bioavailability = 24% (5–67%), less after eating food rich in fat [54] => | protein_bound = ≥98.8% [55] => | metabolism = [[Liver]] [[CYP3A4]], [[CYP3A5]] [56] => | metabolites = [57] => | onset = [58] => | elimination_half-life = 11.3 h for transplant patients (range 3.5–40.6 h) [59] => | duration_of_action = [60] => | excretion = Mostly fecal [61] => [62] => [63] => | CAS_number_Ref = {{cascite|correct|??}} [64] => | CAS_number = 104987-11-3 [65] => | CAS_supplemental = [66] => | PubChem = 445643 [67] => | IUPHAR_ligand = [68] => | DrugBank_Ref = {{drugbankcite|correct|drugbank}} [69] => | DrugBank = DB00864 [70] => | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} [71] => | ChemSpiderID = 393220 [72] => | UNII_Ref = {{fdacite|changed|FDA}} [73] => | UNII = Y5L2157C4J [74] => | KEGG_Ref = {{keggcite|correct|kegg}} [75] => | KEGG = D08556 [76] => | KEGG2_Ref = {{keggcite|correct|kegg}} [77] => | KEGG2 = D00107 [78] => | ChEBI_Ref = [79] => | ChEBI = 61049 [80] => | ChEMBL_Ref = {{ebicite|correct|EBI}} [81] => | ChEMBL = 269732 [82] => | NIAID_ChemDB = [83] => | PDB_ligand = FK5 [84] => | synonyms = FK-506, fujimycin [85] => [86] => [87] => | IUPAC_name = (−)-(3''S'',4''R'',5''S'',8''R'',9''E'',12''S'',14''S'',15''R'',16''S'',18''R'',26a''S'')-8-allyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-{(''E'')-2-[(1''R'',3''R'',4''R'')-4-hydroxy-3-methylcyclohexyl]-1-methylvinyl}-14,16-dimethoxy-4,10,12,18-tetramethyl-15,19-epoxy-3''H''-pyrido[2,1-''c''] [1,4]oxaazacyclotricosane-1,7,20,21(4''H'',23''H'')-tetrone [88] => | C=44 | H=69 | N=1 | O=12 [89] => | SMILES = O=C3C(=O)N1CCCC[C@H]1C(=O)O[C@H](C(=C/[C@@H]2CC[C@@H](O)[C@H](OC)C2)/C)[C@H](C)[C@@H](O)CC(=O)[C@@H](/C=C(/C[C@@H](C[C@H](OC)[C@H]4O[C@]3(O)[C@H](C)C[C@@H]4OC)C)C)C\C=C [90] => | StdInChI_Ref = {{stdinchicite|correct|chemspider}} [91] => | StdInChI = 1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19+,27-21+/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+/m0/s1 [92] => | StdInChI_comment = [93] => | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} [94] => | StdInChIKey = QJJXYPPXXYFBGM-LFZNUXCKSA-N [95] => | density = [96] => | density_notes = [97] => | melting_point = [98] => | melting_high = [99] => | melting_notes = [100] => | boiling_point = [101] => | boiling_notes = [102] => | solubility = [103] => | sol_units = [104] => | specific_rotation = [105] => }} [106] => [107] => '''Tacrolimus''', sold under the brand name '''Prograf''' among others, is an [[immunosuppressive drug]]. After [[Allotransplantation|allogenic]] [[organ transplant]], the risk of organ [[Transplant rejection|rejection]] is moderate. To lower the risk of organ rejection, tacrolimus is given. The drug can also be sold as a [[topical medication]] in the treatment of T-cell-mediated diseases such as [[atopic dermatitis|eczema]] and [[psoriasis]]. For example, it is prescribed for severe refractory [[uveitis]] after a [[bone marrow]] transplant, exacerbations of [[minimal change disease]], [[Kimura's disease]], and [[vitiligo]]. It can be used to treat [[Dry eye syndrome#Other animals|dry eye syndrome]] in cats and dogs.{{cite journal | vauthors = Berdoulay A, English RV, Nadelstein B | title = Effect of topical 0.02% tacrolimus aqueous suspension on tear production in dogs with keratoconjunctivitis sicca | journal = Veterinary Ophthalmology | volume = 8 | issue = 4 | pages = 225–232 | year = 2005 | pmid = 16008701 | doi = 10.1111/j.1463-5224.2005.00390.x | doi-access = free }}{{cite web|title=Tacrolimus for Dogs and Cats|url=https://www.wedgewoodpetrx.com/learning-center/medication-information-for-pet-and-horse-owners/tacrolimus-for-dogs-and-cats.html}} [108] => [109] => Tacrolimus inhibits [[calcineurin]], which is involved in the production of [[interleukin-2]], a [[molecule]] that promotes the development and [[cell proliferation|proliferation]] of [[T cell]]s, as part of the body's learned (or [[adaptive immune response|adaptive]]) immune response. [110] => [111] => Chemically, it is a [[macrolide]] [[lactone]]{{cite journal | vauthors = Baldo A, Cafiero M, Di Caterino P, Di Costanzo L | title = Tacrolimus ointment in the management of atopic dermatitis | journal = Clinical, Cosmetic and Investigational Dermatology | volume = 2 | pages = 1–7 | date = January 2009 | pmid = 21436963 | pmc = 3047924 | doi = 10.2147/ccid.s3378 | doi-access = free }} that was first discovered in 1987, from the fermentation broth of a [[Japan]]ese [[soil]] sample that contained the [[bacterium]] ''[[Streptomyces tsukubensis]]''. It is on the [[WHO Model List of Essential Medicines|World Health Organization's List of Essential Medicines]].{{cite book | vauthors = ((World Health Organization)) | title = The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023) | year = 2023 | hdl = 10665/371090 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MHP/HPS/EML/2023.02 | hdl-access=free }} In 2021, it was the 296th most commonly prescribed medication in the United States, with more than 500,000 prescriptions.{{cite web | title=The Top 300 of 2021 | url=https://clincalc.com/DrugStats/Top300Drugs.aspx | website=ClinCalc | access-date=14 January 2024 | archive-date=15 January 2024 | archive-url=https://web.archive.org/web/20240115223848/https://clincalc.com/DrugStats/Top300Drugs.aspx | url-status=live }}{{cite web | title = Tacrolimus - Drug Usage Statistics | website = ClinCalc | url = https://clincalc.com/DrugStats/Drugs/Tacrolimus | access-date = 14 January 2024}} [112] => [113] => {{TOC limit|3}} [114] => [115] => ==Medical uses== [116] => ===Organ transplantation=== [117] => It has similar immunosuppressive properties to [[ciclosporin]], but is much more potent. Immunosuppression with tacrolimus was associated with a significantly lower rate of acute rejection compared with ciclosporin-based immunosuppression (30.7% vs 46.4%) in one study.{{cite web | vauthors = McCauley J |date=19 May 2004 | url = http://www.medscape.com/viewarticle/474429 | title=Long-Term Graft Survival In Kidney Transplant Recipients | work=Slide Set Series on Analyses of Immunosuppressive Therapies | publisher=[[Medscape]] | access-date=6 June 2006}} Clinical outcome is better with tacrolimus than with ciclosporin during the first year of liver transplantation.{{cite journal | vauthors = Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL | title = Cyclosporin versus tacrolimus for liver transplanted patients | journal = The Cochrane Database of Systematic Reviews | volume = 2006 | issue = 4 | pages = CD005161 | date = October 2006 | pmid = 17054241 | pmc = 8865611 | doi = 10.1002/14651858.CD005161.pub2 | veditors = McAlister V }}{{cite journal | vauthors = O'Grady JG, Burroughs A, Hardy P, Elbourne D, Truesdale A | title = Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial | journal = Lancet | volume = 360 | issue = 9340 | pages = 1119–1125 | date = October 2002 | pmid = 12387959 | doi = 10.1016/S0140-6736(02)11196-2 | s2cid = 10417106 }} Long-term outcome has not been improved to the same extent. Tacrolimus is normally prescribed as part of a post-transplant cocktail including [[corticosteroids|steroids]], [[mycophenolate]], and [[IL-2 receptor]] inhibitors such as [[basiliximab]]. Dosages are titrated to target blood levels at specific times after medication administration.{{cite journal | vauthors = Lee MN, Butani L | title = Improved pharmacokinetic monitoring of tacrolimus exposure after pediatric renal transplantation | journal = Pediatric Transplantation | volume = 11 | issue = 4 | pages = 388–393 | date = June 2007 | pmid = 17493218 | doi = 10.1111/j.1399-3046.2006.00618.x | s2cid = 23530214 | doi-access = free }} [118] => [119] => ===Skin=== [120] => {{See also|Eczema#Medications|l1=Medications used in treatment of eczema}} [121] => [[File:Protopic.JPG|thumb|Tacrolimus 0.1% Ointment]] [122] => [123] => As an [[ointment]], tacrolimus is used in the treatment of [[dermatitis]] (eczema), in particular [[atopic dermatitis]], if topical corticosteroids and moisturisers fail in helping.{{cite journal |vauthors = Cury Martins J, Martins C, Aoki V, Gois AF, Ishii HA, da Silva EM |title = Topical tacrolimus for atopic dermatitis |journal = The Cochrane Database of Systematic Reviews |volume = 2015 |issue = 7 |pages = CD009864 |date = July 2015 |pmid = 26132597 |pmc = 6461158 |doi = 10.1002/14651858.CD009864.pub2 }}{{cite journal |vauthors = Devasenapathy N, Chu A, Wong M, Srivastava A, Ceccacci R, Lin C, MacDonald M, Wen A, Steen J, Levine M, Pyne L, Schneider L, Chu DK |title = Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis |journal = The Lancet. Child & Adolescent Health |volume = 7 |issue = 1 |pages = 13–25 |date = January 2023 |pmid = 36370744 |doi = 10.1016/S2352-4642(22)00283-8 |s2cid = 253470127 }} It suppresses inflammation in a similar way to [[steroid]]s, and is equally as effective as a mid-potency steroid. An important advantage of tacrolimus is that, unlike steroids, it does not cause skin thinning ([[atrophy]]), or other steroid related side effects. [124] => [125] => It is applied on the active lesions until they heal off, but may also be used continuously in low doses (twice a week), and applied to the thinner skin over the face and eyelids.{{Citation needed|date=December 2008}} Clinical trials of up to one year have been conducted. Recently it has also been used to treat segmental [[vitiligo]] in children, especially in areas on the face.{{cite journal |vauthors = Silverberg NB, Lin P, Travis L, Farley-Li J, Mancini AJ, Wagner AM, Chamlin SL, Paller AS |title = Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases |journal = Journal of the American Academy of Dermatology |volume = 51 |issue = 5 |pages = 760–766 |date = November 2004 |pmid = 15523355 |doi = 10.1016/j.jaad.2004.05.036 }} [126] => [127] => ===Eyes=== [128] => Tacrolimus solution, as drops, is sometimes prescribed by veterinarians for [[keratoconjunctivitis]], and other [[dry eye]] maladies, in the eyes of domestic [[cat]]s, [[dog]]s, and [[horse]]s.{{cite web| publisher=[[Plumbs Veterinary Medication Guides]]| title=Tacrolimus, Ophthalmic| date=2017| url=https://www.mspca.org/wp-content/uploads/2017/04/Plumbs-Tacrolimus-Ophthalmic.pdf| access-date=5 August 2022| archive-date=18 December 2022| archive-url=https://web.archive.org/web/20221218152242/https://www.mspca.org/wp-content/uploads/2017/04/Plumbs-Tacrolimus-Ophthalmic.pdf| url-status=dead}} It has been studied for use in human eyes.{{cite web| publisher=U.S. National Library of Medicine| title=Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops| date=10 May 2013| url=https://clinicaltrials.gov/ct2/show/NCT01850979| access-date=5 August 2022| vauthors = Naves FE, Sakassegawa E }}{{cite journal | vauthors = Yazu H, Fukagawa K, Shimizu E, Sato Y, Fujishima H | title = Long-term outcomes of 0.1% tacrolimus eye drops in eyes with severe allergic conjunctival diseases | journal = Allergy, Asthma, and Clinical Immunology | volume = 17 | issue = 1 | pages = 11 | date = February 2021 | pmid = 33522964 | pmc = 7852099 | doi = 10.1186/s13223-021-00513-w | doi-access = free }} [129] => [130] => ==Contraindications and precautions== [131] => Contraindications and precautions include: [132] => * [[Hepatic]] disease [133] => * Immunosuppression [134] => * [[Infant]]s [135] => * [[Infection]] [136] => * [[Neoplastic]] disease, such as: [137] => ** [[Skin cancer]] [138] => ** [[Lung cancer]] [139] => * [[Oliguria]] [140] => * [[Pregnancy]] [141] => * [[QT interval]] prolongation [142] => * [[Sunlight]] ([[UV]]) exposure [143] => * [[Grapefruit]] juice{{cite journal | vauthors = Fukatsu S, Fukudo M, Masuda S, Yano I, Katsura T, Ogura Y, Oike F, Takada Y, Inui K | title = Delayed effect of grapefruit juice on pharmacokinetics and pharmacodynamics of tacrolimus in a living-donor liver transplant recipient | journal = Drug Metabolism and Pharmacokinetics | volume = 21 | issue = 2 | pages = 122–125 | date = April 2006 | pmid = 16702731 | doi = 10.2133/dmpk.21.122 }} [144] => [145] => ===Topical use=== [146] => * Occlusive dressing [147] => * Known or suspected malignant lesions [148] => * [[Netherton's syndrome]] or similar skin diseases [149] => * Certain skin infections{{cite book|title=Austria-Codex|editor=Haberfeld, H|at=Protopic|publisher=Österreichischer Apothekerverlag|location=Vienna|year=2015|language=de}} [150] => [151] => ==Side effects== [152] => ===By mouth or intravenous use=== [153] => Side effects can be severe and include [[infection]], cardiac damage, [[hypertension]], [[blurred vision]], liver and [[kidney]] problems (tacrolimus [[nephrotoxicity]]),{{cite journal | vauthors = Naesens M, Kuypers DR, Sarwal M | title = Calcineurin inhibitor nephrotoxicity | journal = Clinical Journal of the American Society of Nephrology | volume = 4 | issue = 2 | pages = 481–508 | date = February 2009 | pmid = 19218475 | doi = 10.2215/CJN.04800908 | doi-access = free }} [[hyperkalemia]], [[hypomagnesemia]], [[hyperglycemia]], [[diabetes mellitus]], [[itch]]ing, lung damage ([[sirolimus]] also causes lung damage),{{cite journal | vauthors = Miwa Y, Isozaki T, Wakabayashi K, Odai T, Matsunawa M, Yajima N, Negishi M, Ide H, Kasama T, Adachi M, Hisayuki T, Takemura T | title = Tacrolimus-induced lung injury in a rheumatoid arthritis patient with interstitial pneumonitis | journal = Modern Rheumatology | volume = 18 | issue = 2 | pages = 208–211 | year = 2008 | pmid = 18306979 | doi = 10.1007/s10165-008-0034-3 | s2cid = 39537409 }} and various neuropsychiatric problems such as loss of appetite, [[insomnia]], [[posterior reversible encephalopathy syndrome]], confusion, weakness, [[Depression (mood)|depression]], vivid nightmares, [[cramp]]s, [[neuropathy]], [[seizure]]s, [[tremor]]s, and [[catatonia]].{{cite journal | vauthors = O'Donnell MM, Williams JP, Weinrieb R, Denysenko L | title = Catatonic mutism after liver transplant rapidly reversed with lorazepam | journal = General Hospital Psychiatry | volume = 29 | issue = 3 | pages = 280–281 | year = 2007 | pmid = 17484951 | doi = 10.1016/j.genhosppsych.2007.01.004 }} [154] => [155] => [156] => In addition, it may potentially increase the severity of existing fungal or infectious conditions such as [[varicella-zoster virus|herpes zoster]] or [[polyomavirus|polyoma]] viral infections. [157] => [158] => ====Carcinogenesis and mutagenesis==== [159] => In people receiving immunosuppressants to reduce transplant graft rejection, an increased risk of malignancy (cancer) is a recognised complication. The most common cancers are [[non-Hodgkin's lymphoma]]{{Cite web|url=https://www.cancer.org/cancer/non-hodgkin-lymphoma/about/key-statistics.html|title=Key Statistics for Non-Hodgkin Lymphoma|website=www.cancer.org|access-date=19 February 2020}} and [[skin cancer]]s. The risk appears to be related to the intensity and duration of treatment. [160] => [161] => ===Topical use=== [162] => The most common adverse events associated with the use of topical tacrolimus ointments, especially if used over a wide area, include a burning or itching sensation on the initial applications, with increased sensitivity to sunlight and heat on the affected areas.{{Citation needed|date=January 2022}} Less common are [[flu-like symptoms]], headache, cough, and burning eyes.{{cite journal | vauthors = Hanifin JM, Paller AS, Eichenfield L, Clark RA, Korman N, Weinstein G, Caro I, Jaracz E, Rico MJ | title = Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis | journal = Journal of the American Academy of Dermatology | volume = 53 | issue = 2 Suppl 2 | pages = S186–S194 | date = August 2005 | pmid = 16021174 | doi = 10.1016/j.jaad.2005.04.062 }} [163] => [164] => ====Cancer risks==== [165] => {{Further|Eczema#Medications}} [166] => Tacrolimus and a related drug for eczema ([[pimecrolimus]]) were suspected of carrying a cancer risk, though the matter is still a subject of controversy. The FDA issued a health warning in March 2005 for the drug, based on animal models and a small number of patients. Until further human studies yield more conclusive results, the FDA recommends that users be advised of the potential risks. However, current practice by [[United Kingdom|UK]] dermatologists is not to consider this a significant real concern and they are increasingly recommending the use of these new drugs.{{cite web | vauthors = Cox NH, Smith CH |date=December 2002 |url=http://www.bad.org.uk/Portals/_Bad/Guidelines/Position%20Statements%20&%20Other%20Documents/Advice%20re%20topical%20tacrolimus.pdf |title=Advice to dermatologists re topical tacrolimus |work=Therapy Guidelines Committee |publisher=British Association of Dermatologists |url-status=dead |archive-url=https://web.archive.org/web/20131213072822/http://www.bad.org.uk/Portals/_Bad/Guidelines/Position%20Statements%20%26%20Other%20Documents/Advice%20re%20topical%20tacrolimus.pdf |archive-date=13 December 2013 }} A 2023 systematic review and meta-analysis published in [[The Lancet Child & Adolescent Health]] concluded with moderate-certainty evidence that the two drugs were not associated with any increased risk of cancer.{{cite journal | vauthors = Devasenapathy N, Chu A, Wong M, Srivastava A, Ceccacci R, Lin C, MacDonald M, Wen A, Steen J, Levine M, Pyne L, Schneider L, Chu DK | title = Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis | language = English | journal = The Lancet. Child & Adolescent Health | volume = 7 | issue = 1 | pages = 13–25 | date = January 2023 | pmid = 36370744 | doi = 10.1016/S2352-4642(22)00283-8 | s2cid = 253470127 }} [167] => [168] => == Interactions == [169] => [170] => Also like cyclosporin, it has a wide range of interactions. Tacrolimus is primarily metabolised by the [[cytochrome P450]] system of liver enzymes, and there are many substances that interact with this system and induce or inhibit the system's metabolic activity.{{cite book|title=Austria-Codex|editor=Haberfeld, H|at=Prograf|publisher=Österreichischer Apothekerverlag|location=Vienna|year=2015|language=de}} [171] => [172] => Interactions include that with [[grapefruit]] which increases tacrolimus plasma concentrations. As infections are a major cause of morbidity and mortality in the post-transplant patient, the most commonly{{citation needed|date=October 2016}} reported interactions include interactions with anti-microbial drugs. Macrolide antibiotics including [[erythromycin]] and [[clarithromycin]], as well as several of the newer classes of antifungals, especially of the azole class ([[fluconazole]], [[voriconazole]]), increase tacrolimus levels by competing for cytochrome enzymes. [173] => [174] => ==Pharmacology== [175] => ===Mechanism of action=== [176] => [[File:PDB 1fkk EBI.jpg|thumb|[[FKBP12]], the target protein of tacrolimus]] [177] => Tacrolimus is a [[macrolide]] [[calcineurin inhibitor]]. In [[T-cells]], activation of the T-cell receptor normally increases intracellular calcium, which acts via [[calmodulin]] to activate [[calcineurin]]. Calcineurin then dephosphorylates the transcription factor [[nuclear factor of activated T-cells]] (NF-AT), which moves to the nucleus of the T-cell and increases the activity of genes coding for IL-2 and related cytokines. Tacrolimus prevents the dephosphorylation of NF-AT.{{cite book| vauthors = Ganong WF |title= Review of medical physiology|edition=22nd |publisher=Lange medical books|page=530|isbn=978-0-07-144040-0|date= 8 March 2005}} [178] => [179] => In detail, tacrolimus reduces [[Peptidylprolyl isomerase A|peptidylprolyl isomerase]] activity by binding to the immunophilin [[FKBP12]] (FK506 binding protein), creating a new complex. This FKBP12–FK506 complex interacts with and inhibits calcineurin, thus inhibiting both T-[[lymphocyte]] signal transduction and IL-2 transcription.{{cite journal | vauthors = Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL | title = Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes | journal = Cell | volume = 66 | issue = 4 | pages = 807–815 | date = August 1991 | pmid = 1715244 | doi = 10.1016/0092-8674(91)90124-H | s2cid = 22094672 }} Although this activity is similar to that of cyclosporin, the incidence of acute rejection is reduced by tacrolimus use over cyclosporin use. Although short-term immunosuppression concerning patient and graft survival is found to be similar between the two drugs, tacrolimus results in a more favorable lipid profile, and this may have important long-term implications given the prognostic influence of rejection on graft survival.{{cite journal | vauthors = Abou-Jaoude MM, Najm R, Shaheen J, Nawfal N, Abboud S, Alhabash M, Darwish M, Mulhem A, Ojjeh A, Almawi WY | title = Tacrolimus (FK506) versus cyclosporine microemulsion (neoral) as maintenance immunosuppression therapy in kidney transplant recipients | journal = Transplantation Proceedings | volume = 37 | issue = 7 | pages = 3025–3028 | date = September 2005 | pmid = 16213293 | doi = 10.1016/j.transproceed.2005.08.040 }} [180] => [181] => ===Pharmacokinetics=== [182] => Oral tacrolimus is slowly absorbed in the [[gastrointestinal tract]], with a total [[bioavailability]] of 20 to 25% (but with variations from 5 to 67%) and [[Cmax (pharmacology)|highest blood plasma concentrations]] (Cmax) reached after one to three hours. Taking the drug together with a meal, especially one rich in fat, slows down resorption and reduces bioavailability. In the blood, tacrolimus is mainly bound to [[erythrocyte]]s; only 5% are found in the [[blood plasma|plasma]], of which more than 98.8% are bound to [[plasma protein]]s.{{cite book|title=Arzneistoff-Profile|editor1=Dinnendahl, V |editor2=Fricke, U |publisher=Govi Pharmazeutischer Verlag|location=Eschborn, Germany|date=2003|edition=18|volume=9|isbn=978-3-7741-9846-3|language=de}} [183] => [184] => The substance is metabolized in the liver, mainly via [[CYP3A]], and in the intestinal wall. All [[metabolite]]s found in the circulation are inactive. [[Biological half-life]] varies widely and seems to be higher for healthy persons (43 hours on average) than for patients with liver transplants (12 hours) or kidney transplants (16 hours), due to differences in [[clearance (pharmacology)|clearance]]. Tacrolimus is predominantly eliminated via the faeces in form of its metabolites. [185] => [186] => When applied locally on eczema, tacrolimus has little to no bioavailability. [187] => [188] => ===Pharmacogenetics=== [189] => The predominant enzyme responsible for metabolism of tacrolimus is [[CYP3A5]]. [[Genetic variation]]s within ''CYP3A5'' that result in changes to the activity of the CYP3A5 protein can affect concentrations of tacrolimus within the body. In particular, individuals who are [[homozygous]] for the G [[allele]] at the [[single nucleotide polymorphism]] (SNP) rs776746 (also known as CYP3A5 *3/*3) have a non-functional CYP3A5 protein. The frequency of the G allele varies worldwide, from 4% in some African populations to 80–90% in Caucasian populations.{{cite web| vauthors = Bains RK |title=Molecular diversity and population structure at the CYP3A5 gene in Africa|url=http://discovery.ucl.ac.uk/1356293/7/1356293_R%20Bains%20ELECTRONIC%20VERSION%20thesis%20-%20post%20viva.pdf|publisher=University College London|access-date=13 June 2016}} Across a large number of studies, individuals homozygous for the G allele have been shown to have higher concentrations of tacrolimus and require lower doses of the drug, as compared to individuals who are not homozygous for the G allele. Achieving target concentrations of tacrolimus is important – if levels are too low, then there is a risk of [[transplant rejection]], if levels are too high, there is a risk of drug toxicities. There is evidence to suggest that dosing patients based on rs776746 [[genotype]] can result in faster and more frequent achievement of target tacrolimus levels. However, there is a lack of consistent evidence as to whether dosing based on rs776746 genotype results in improved clinical outcomes (such as a decreased risk for transplant rejection or drug toxicities), likely because patients taking tacrolimus are subject to [[therapeutic drug monitoring]].{{cite journal | vauthors = Staatz CE, Tett SE | title = Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation | journal = Clinical Pharmacokinetics | volume = 43 | issue = 10 | pages = 623–653 | date = 2004 | pmid = 15244495 | doi = 10.2165/00003088-200443100-00001 | s2cid = 33877550 }}{{cite journal | vauthors = Staatz CE, Goodman LK, Tett SE | title = Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I | journal = Clinical Pharmacokinetics | volume = 49 | issue = 3 | pages = 141–175 | date = March 2010 | pmid = 20170205 | doi = 10.2165/11317350-000000000-00000 | s2cid = 28346861 }}{{cite journal | vauthors = Staatz CE, Goodman LK, Tett SE | title = Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II | journal = Clinical Pharmacokinetics | volume = 49 | issue = 4 | pages = 207–221 | date = April 2010 | pmid = 20214406 | doi = 10.2165/11317550-000000000-00000 | s2cid = 27047235 }}{{cite journal | vauthors = Barbarino JM, Staatz CE, Venkataramanan R, Klein TE, Altman RB | title = PharmGKB summary: cyclosporine and tacrolimus pathways | journal = Pharmacogenetics and Genomics | volume = 23 | issue = 10 | pages = 563–585 | date = October 2013 | pmid = 23922006 | pmc = 4119065 | doi = 10.1097/fpc.0b013e328364db84 }} [190] => [191] => Studies have shown that genetic polymorphisms of genes other than CYP3A5, such as NR1I2{{cite journal | vauthors = Benkali K, Prémaud A, Picard N, Rérolle JP, Toupance O, Hoizey G, Turcant A, Villemain F, Le Meur Y, Marquet P, Rousseau A | title = Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients | journal = Clinical Pharmacokinetics | volume = 48 | issue = 12 | pages = 805–816 | date = 1 January 2009 | pmid = 19902988 | doi = 10.2165/11318080-000000000-00000 | s2cid = 19900291 }}{{cite journal | vauthors = Choi Y, Jiang F, An H, Park HJ, Choi JH, Lee H | title = A pharmacogenomic study on the pharmacokinetics of tacrolimus in healthy subjects using the DMETTM Plus platform | journal = The Pharmacogenomics Journal | volume = 17 | issue = 1 | pages = 105–106 | date = January 2017 | pmid = 27958377 | doi = 10.1038/tpj.2016.85 | doi-access = free }} (encoding [[Pregnane X receptor|PXR]]), also significantly influence the pharmacokinetics of tacrolimus. [192] => [193] => ==History== [194] => Tacrolimus was discovered in 1987; it was among the first macrolide immunosuppressants discovered, preceded by the discovery of [[rapamycin]] (sirolimus) on [[Rapa Nui]] (Easter Island) in 1975.{{cite journal | vauthors = Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, Kohsaka M, Aoki H, Imanaka H | title = FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics | journal = The Journal of Antibiotics | volume = 40 | issue = 9 | pages = 1249–1255 | date = September 1987 | pmid = 2445721 | doi = 10.7164/antibiotics.40.1249 | doi-access = free }} It is produced by a soil bacterium, ''Streptomyces tsukubensis''.{{cite journal | vauthors = Pritchard DI | title = Sourcing a chemical succession for cyclosporin from parasites and human pathogens | journal = Drug Discovery Today | volume = 10 | issue = 10 | pages = 688–691 | date = May 2005 | pmid = 15896681 | doi = 10.1016/S1359-6446(05)03395-7 }} Supports source organism, but not team information The name tacrolimus is derived from "[[Mount Tsukuba|Tsukuba]] macrolide immunosuppressant".Ponner, B, Cvach, B (Fujisawa Pharmaceutical Co.): Protopic Update 2005 [195] => [196] => The early development (investigational new drug phase) of tacrolimus, called at the time by the development code FK-506, happened in the next several years. A firsthand account of that process is given in [[Thomas Starzl]]'s 1992 memoir.{{cite book |last=Starzl |first=Thomas E. |date=1992 |chapter=Chapter 25: The drug with no name |pages=288–308 |title=The Puzzle People: Memoirs Of A Transplant Surgeon |publisher=University of Pittsburgh Press |doi=10.2307/j.ctt9qh63b |isbn=978-0-8229-3714-2 |url=https://doi.org/10.2307/j.ctt9qh63b}} [197] => [198] => Tacrolimus was first [[FDA approval|approved]] by the US [[Food and Drug Administration]] (FDA) in 1994,{{cite web | title=Prograf: FDA-Approved Drugs | website=U.S. [[Food and Drug Administration]] (FDA) | url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050708 | access-date=29 April 2020}}{{cite web | title=Prograf: FDA-Approved Drugs | website=U.S. [[Food and Drug Administration]] (FDA) | url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050709 | access-date=29 April 2020}} for use in [[liver transplantation]]; the indications were extended to include kidney transplants.Tacrolimus (Systemic) {{drugs.com|monograph|tacrolimus}}. Accessed 16 December 2021. Generic versions of tacrolimus were approved in the US in 2017.{{cite web | title=Tacrolimus: FDA-Approved Drugs | website=U.S. [[Food and Drug Administration]] (FDA) | url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203900 | access-date=29 April 2020}} [199] => [200] => Tacrolimus was approved for medical use in the European Union in 2002, for the treatment of moderate to severe atopic dermatitis.{{cite web | title=Protopic EPAR | website=[[European Medicines Agency]] (EMA) | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/protopic | access-date=29 April 2020}} {{PD-notice}} In 2007, the indications were expanded to include the prophylaxis of transplant rejection in adult kidney or liver allograft recipients and the treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adults.{{cite web | title=Advagraf EPAR | website=[[European Medicines Agency]] (EMA) | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/advagraf | access-date=29 April 2020}} {{PD-notice}} In 2009, the indications were expanded to include the prophylaxis of transplant rejection in adult and paediatric, kidney, liver or heart allograft recipients and the treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adults and children.{{cite web | title=Modigraf EPAR | website=[[European Medicines Agency]] (EMA) | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/modigraf | access-date=29 April 2020}} [201] => [202] => ==Available forms== [203] => A branded version of the drug is owned by [[Astellas Pharma]], and is sold under the brand name Prograf, given twice daily. A number of other manufacturers hold marketing authorisation for alternative brands of the twice-daily formulation.{{cite web|last1=Joint Formulary Committee|title=British National Formulary (online)|url=http://www.medicinescomplete.com/|publisher=London: BMJ Group and Pharmaceutical Press|access-date=24 September 2015}} [204] => [205] => Once-daily formulations with marketing authorisation include Advagraf (Astellas Pharma) and Envarsus (marketed as Envarsus XR in US by [[Veloxis Pharmaceuticals]] and marketed in Europe by [[Chiesi Farmaceutici S.p.A.|Chiesi]]). These formulations are intended to reduce pharmacokinetic variation in blood levels and facilitate compliance with dosing.{{citation needed|date=April 2020}} [206] => [207] => The topical formulation is marketed by [[LEO Pharma]] under the name '''Protopic'''. [208] => [209] => ==Biosynthesis== [210] => [211] => [[File:Tacrolimus biosynthesis part 1.tif|300px]] [212] => [[File:Tacrolimus biosynthesis part 2.tif|300px]] [213] => [[File:Tacrolimus biosynthesis part 3..tif|300px]] [214] => [215] => The biosynthesis of tacrolimus is hybrid synthesis of both type 1 [[polyketide synthases]] (PKS 1) and [[nonribosomal peptide]] syntheses (NRPS). The research shows the hybrid synthesis consists of ten modules of type 1 polyketide synthase and one module of nonribosomal peptide synthase. The synthetic enzymes for tacrolimus are found in 19 gene clusters named fkb. The 19 genes are fkbQ, fkbN, fkbM, fkbD, fkbA, fkbP, fkbO, fkbB, fkbC, fkbL, fkbK, fkbJ, fkbI, fkbH, fkbG, allD, allR, allK and allA.{{cite journal | vauthors = Ordóñez-Robles M, Santos-Beneit F, Martín JF | title = Unraveling Nutritional Regulation of Tacrolimus Biosynthesis in ''Streptomyces tsukubaensis'' through ''omic'' Approaches | journal = Antibiotics | volume = 7 | issue = 2 | pages = 39 | date = May 2018 | pmid = 29724001 | pmc = 6022917 | doi = 10.3390/antibiotics7020039 | doi-access = free }} [216] => [217] => There are several possible ways of biosynthesis of tacrolimus. The fundamental units for biosynthesis are following: one molecule of 4,5-dihydroxycyclohex-1-enecarboxylic acid (DHCHC) as a starter unit, four molecules of malonyl-CoA, five molecules of methylmalonyl-CoA, one molecule of allylmalonyl-CoA as elongation units. However, two molecules of malonyl-CoA are able to be replaced by two molecules of methoxymalonyl CoA. Once two malonyl-CoA molecules are replaced, post-synthase tailoring steps are no longer required where two methoxymalonyl CoA molecules are substituted. The biosynthesis of methoxymalonyl CoA to Acyl Carrier protein is proceeded by five enzymes (fkbG, fkbH, fkbI, fkbJ, and fkbK). Allylmalonyl-CoA is also able to be replaced by propionylmalonyl-CoA. [218] => [219] => The starter unit, DHCHC from the [[chorismic acid]] is formed by fkbO enzyme and loaded onto CoA-ligase domain (CoL). Then, it proceeds to NADPH dependent reduction(ER). Three enzymes, fkbA,B,C enforce processes from the loading module to the module 10, the last step of PKS 1. fkbB enzyme is responsible of allylmalonyl-CoA synthesis or possibly propionylmalonyl-CoA at C21, which it is an unusual step of general PKS 1. As mentioned, if two methoxymalonyl CoA molecules are substituted for two malonyl-CoA molecules, they will take place in module 7 and 8 (C13 and C15), and fkbA enzyme will enforce this process. After the last step (module 10) of PKS 1, one molecule of L-[[pipecolic acid]] formed from L-[[lysine]] and catalyzed through fkbL enzyme synthesizes with the molecule from the module 10. The process of L-pipecolic acid synthesis is NRPS enforced by fkbP enzyme. After synthesizing the entire subunits, the molecule is cyclized. After the cyclization, the pre-tacrolimus molecule goes through the post-synthase tailoring steps such as oxidation and [[S-Adenosyl methionine|''S''-adenosyl methionine]]. Particularly fkbM enzyme is responsible of alcohol methylation targeting the alcohol of DHCHC starter unit (Carbon number 31 depicted in brown), and fkbD enzyme is responsible of C9 (depicted in green). After these tailoring steps, the tacrolimus molecule becomes biologically active.{{cite journal | vauthors = Chen D, Zhang L, Pang B, Chen J, Xu Z, Abe I, Liu W | title = FK506 maturation involves a cytochrome p450 protein-catalyzed four-electron C-9 oxidation in parallel with a C-31 O-methylation | journal = Journal of Bacteriology | volume = 195 | issue = 9 | pages = 1931–1939 | date = May 2013 | pmid = 23435975 | pmc = 3624582 | doi = 10.1128/JB.00033-13 }}{{cite journal | vauthors = Mo S, Ban YH, Park JW, Yoo YJ, Yoon YJ | title = Enhanced FK506 production in Streptomyces clavuligerus CKD1119 by engineering the supply of methylmalonyl-CoA precursor | journal = Journal of Industrial Microbiology & Biotechnology | volume = 36 | issue = 12 | pages = 1473–1482 | date = December 2009 | pmid = 19756799 | doi = 10.1007/s10295-009-0635-7 | s2cid = 32967249 | doi-access = free }} [220] => [221] => == Research == [222] => ===Lupus nephritis=== [223] => Tacrolimus has been shown to reduce the risk of serious infections while also increasing [[remission (medicine)|remission]] of kidney function in [[lupus nephritis]].{{cite journal | vauthors = Singh JA, Hossain A, Kotb A, Wells G | title = Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis | journal = BMC Medicine | volume = 14 | issue = 1 | pages = 137 | date = September 2016 | pmid = 27623861 | pmc = 5022202 | doi = 10.1186/s12916-016-0673-8 | doi-access = free }}{{cite journal | vauthors = Singh JA, Hossain A, Kotb A, Wells GA | title = Comparative effectiveness of immunosuppressive drugs and corticosteroids for lupus nephritis: a systematic review and network meta-analysis | journal = Systematic Reviews | volume = 5 | issue = 1 | pages = 155 | date = September 2016 | pmid = 27619512 | pmc = 5020478 | doi = 10.1186/s13643-016-0328-z | doi-access = free }} [224] => [225] => ===Ulcerative colitis=== [226] => Tacrolimus has been used to suppress the inflammation associated with [[ulcerative colitis]] (UC), a form of [[inflammatory bowel disease]]. Although almost exclusively used in trial cases only, tacrolimus has shown to be significantly effective in the suppression of flares of UC.{{cite journal | vauthors = Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU | title = Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up | journal = The American Journal of Gastroenterology | volume = 101 | issue = 5 | pages = 1048–1056 | date = May 2006 | pmid = 16573777 | doi = 10.1111/j.1572-0241.2006.00524.x | s2cid = 10233231 }} A 2022 updated Cochrane systematic review found that tacrolimus may be superior to placebo in achieving remission and improvement in UC.{{cite journal | vauthors = Gordon M, Sinopoulou V, Akobeng AK, Pana M, Gasiea R, Moran GW | title = Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis | journal = The Cochrane Database of Systematic Reviews | volume = 2022 | issue = 4 | pages = CD007216 | date = April 2022 | pmid = 35388476 | pmc = 8987360 | doi = 10.1002/14651858.CD007216.pub2 }} [227] => [228] => == References == [229] => {{Reflist}} [230] => [231] => == Further reading == [232] => {{refbegin}} [233] => * {{cite journal | vauthors = Lv X, Qi J, Zhou M, Shi B, Cai C, Tang Y, Pan T, Han Y | title = Comparative efficacy of 20 graft-versus-host disease prophylaxis therapies for patients after hematopoietic stem-cell transplantation: A multiple-treatments network meta-analysis | journal = Critical Reviews in Oncology/Hematology | volume = 150 | pages = 102944 | date = June 2020 | pmid = 32247246 | doi = 10.1016/j.critrevonc.2020.102944 | s2cid = 214794350 }} [234] => {{refend}} [235] => [236] => == External links == [237] => * {{cite web | title=Tacrolimus Injection | website=MedlinePlus | url=https://medlineplus.gov/druginfo/meds/a608037.html }} [238] => * {{cite web | title=Tacrolimus Topical | website=MedlinePlus | url=https://medlineplus.gov/druginfo/meds/a602020.html }} [239] => * {{MeSH name|Tacrolimus}} [240] => * {{cite web | title=FDA Approves New Use of Transplant Drug Based on Real-World Evidence | website=U.S. [[Food and Drug Administration]] (FDA) | date=30 September 2021 | url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-new-use-transplant-drug-based-real-world-evidence }} [241] => [242] => {{Other dermatological preparations}} [243] => {{Immunosuppressants}} [244] => {{Xenobiotic-sensing receptor modulators}} [245] => {{Portal bar | Medicine}} [246] => {{Authority control}} [247] => [248] => [[Category:Astellas Pharma]] [249] => [[Category:CYP3A4 inhibitors]] [250] => [[Category:Disulfiram-like drugs]] [251] => [[Category:Immunosuppressants]] [252] => [[Category:Macrolides]] [253] => [[Category:Nephrotoxins]] [254] => [[Category:Orphan drugs]] [255] => [[Category:World Health Organization essential medicines]] [256] => [[Category:Allyl compounds]] [257] => [[Category:Alkene derivatives]] [] => )
good wiki

Tacrolimus

Tacrolimus is a medication used to suppress the immune system and prevent the rejection of organ transplants. It belongs to a class of drugs known as calcineurin inhibitors and is primarily used in kidney, liver, and heart transplants.

More about us

About

It belongs to a class of drugs known as calcineurin inhibitors and is primarily used in kidney, liver, and heart transplants. The medication works by inhibiting the activation of T-lymphocytes, a type of white blood cell involved in immune responses. Tacrolimus is available as a topical ointment for the treatment of eczema and as an oral capsule or injection for transplant patients. While effective in preventing organ rejection, tacrolimus can have several side effects, including increased risk of infections, kidney toxicity, and unwanted hair growth. Regular monitoring of blood levels is required to ensure safe and effective use of the medication.

Expert Team

Vivamus eget neque lacus. Pellentesque egauris ex.

Award winning agency

Lorem ipsum, dolor sit amet consectetur elitorceat .

10 Year Exp.

Pellen tesque eget, mauris lorem iupsum neque lacus.

You might be interested in

Allotransplantation

Allotransplant (allo- meaning "other" in Greek) is the transplantation of cells, tissues, or organs to a recipient from a genetically non-identical donor of the same species.

CYP3A4

CYP3A4 is an enzyme that belongs to the cytochrome P450 family and is primarily found in the liver.

Dog

The Wikipedia page on dogs provides a comprehensive overview of the domestic dog, a highly popular and beloved companion animal.

Erythrocyte

Erythromycin

Erythromycin is a broad-spectrum macrolide antibiotic that is commonly used in the treatment of various bacterial infections.

Horse

"Horse" is a Wikipedia page that provides comprehensive information about the domesticated equine species called horse.

Infant

Infancy, often referred to as infancy stage, is the earliest period of childhood, typically lasting from birth to two years of age.

Kidney

The kidney is an essential organ in the human body responsible for filtering waste products and excess water from the bloodstream, producing urine, and maintaining proper levels of electrolytes and fluids.

Liver

The liver is an organ in the human body located in the upper right abdomen.

Molecule

A molecule is a group of atoms bonded together, representing the smallest fundamental unit of a chemical compound that can take part in a chemical reaction.

Soil

Soil is a natural resource that forms the upper layer of the Earth's crust.

Voriconazole

Voriconazole, sold under the brand name Vfend among others, is an antifungal medication used to treat a number of fungal infections.